| 1 |
房延凤，马李杰，刘雁声，等. 非小细胞肺癌E19-Del、L858R突变临床特征分析[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(2): 164-168.
|
| 2 |
Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update[J]. Discov Med, 2019, 27(148): 167-170.
|
| 3 |
Proto C, Ferrara R, Signorelli D, et al. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out[J]. Cancer Treat Rev, 2019, 75(1): 39-51.
|
| 4 |
Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC[J]. Nat Rev Clin Oncol, 2019, 16(6): 341-355.
|
| 5 |
Le X, Nilsson M, Goldman J, et al. Dual EGFR-VEGF pathway inhibition: A promising strategy for patients with EGFR-mutant NSCLC[J]. J Thorac Oncol, 2021, 16(2): 205-215.
|
| 6 |
李 会，卓 情，武琦放，等. F0XP3通过靶向S100A6启动子促进肺腺癌细胞迁移[J]. 生物技术，2021, 31(1): 16-25.
|
| 7 |
李 鹏，梁跃东，刘建西，等. 基于数据挖掘分析S100A6在肝细胞癌中的表达及临床意义[J]. 现代肿瘤医学，2020, 28(12): 2089-2094.
|
| 8 |
张丽红，方晓婷，董学君. 血清S100B蛋白对肺癌脑转移的诊断价值[J]. 医学研究杂志，2019, 48(1): 52-55.
|
| 9 |
石远凯，孙 燕，丁翠敏，等. 中国埃克替尼治疗非小细胞肺癌专家共识(2016年版)[J]. 中国肺癌杂志，2016, 19(7): 489-493.
|
| 10 |
Balata H, Fong KM, Hendriks LE, et al. Prevention and early detection for NSCLC: Advances in thoracic oncology 2018[J]. J Thorac Oncol, 2019, 14(9): 1513-1527.
|
| 11 |
Duma N, Santana-Davila R, Molina JR. Non-small cell lung Cancer: Epidemiology, screening, diagnosis, and treatment [J]. Mayo Clin Proc, 2019, 94(8): 1623-1640.
|
| 12 |
白 莹，马 娟，吕 欣，等. 慢性阻塞性肺疾病合并肺癌临床特征分析[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(3): 265-271.
|
| 13 |
Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives[J]. Crit Rev Oncol Hematol, 2021, 157(1): 103-104.
|
| 14 |
胡守军，李文涛，孙仲涛. MOB1表达水平与非小细胞肺癌切除术后疾病进展风险的相关性[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(3): 332-334.
|
| 15 |
Meador CB, Hata AN. Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights [J]. Pharmacol Ther, 2020, 210(7): 107522.
|
| 16 |
Pennell NA, Arcila ME, Gandara DR, et al. Biomarker testing for patients with advanced non-small cell lung cancer: Real-world issues and tough choices[J]. Am Soc Clin Oncol Educ Book, 2019, 39(2): 531-542.
|
| 17 |
苏 菁，钱海红，李 琛，等. 血清S100B对小细胞肺癌脑转移的预测价值研究[J]. 临床肺科杂志，2019, 24(5): 877-880.
|
| 18 |
张丽红，王宏斌，胡良峰. 血清S100B自身抗体在肺癌脑转移中的应用价值[J]. 中国卫生检验杂志，2020, 30(14): 1713-1715.
|
| 19 |
耿 楠，丁翠敏，胡文霞，等. NSCLC脑转移患者血清S100B、外泌体miR 330表达及临床意义[J]. 临床肿瘤学杂志，2020, 25(10): 888-894.
|
| 20 |
杨 莹，吴小玲，邓治平. 血清S100A2和S100A6浓度对非小细胞肺癌患者诊断价值[J]. 国际呼吸杂志，2019, 39(23): 1769-1773.
|
| 21 |
屈晓一，王 婷，白乐乐. S100A6通过抑制细胞分裂、迁移、侵袭及促进凋亡抑制Calu-6肺癌细胞株生长[J]. 国际呼吸杂志，2021, 41(17): 1315-1321.
|
| 22 |
鲍 慧，年 亮，秦妮娜. 不同基因分型复发或转移晚期非小细胞肺癌患者的临床特征及预后影响因素分析[J]. 癌症进展，2019, 17(18): 2162-2166.
|
| 23 |
李 锋，毛友生．Ⅰ期非小细胞肺癌预后影响因素的研究进展[J]. 中国肿瘤，2019, 28(7): 523-528.
|
| 24 |
李 婵，李 涛. 老年非小细胞肺癌患者预后影响因素分析[J]. 中华肿瘤防治杂志，2020, 27(22): 1844-1849.
|
| 25 |
唐中豪，林 开，李向阳，等. 非小细胞肺癌患者临床疗效及预后的影响因素[J]. 老年医学与保健，2021, 27(2): 245-249.
|
| 26 |
张惠姗，王捷忠，张 伟，等. 局部晚期非小细胞肺癌患者放化疗的预后相关因素分析[J]. 福建医科大学学报，2019, 53(4): 235-240.
|
| 27 |
Gutierrez ME, Choi K, Lanman RB, et al. Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities[J]. Clin Lung Cancer, 2017, 18(6): 651-659.
|
| 28 |
Song Y, Zhou Q, Zhang X, et al. Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage ⅢB/Ⅳ nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506)[J]. Lung Cancer, 2018, 123: 7-13.
|
| 29 |
Rajadurai P, Cheah PL, How SH, et al. Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society[J]. Lung Cancer, 2019, 136: 65-73.
|
| 30 |
Friedlaender A, Banna G, Patel S, et al. Diagnosis and treatment of ALK aberrations in metastatic NSCLC[J]. Curr Treat Options Oncol, 2019, 20(10): 79.
|